Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.48 |
| ▸ | CCR2 | P41597 | 9/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1262739 | 0.98 | ADRA1D (0.47) | ADRA1DCCR2ADRA1AADRA1BTRPV4 | |
| SCHEMBL3922915 | 0.85 | CCR2 (0.41) | ADRA1DCCR2ADRA1AADRA1BL3MBTL1 | |
| SCHEMBL30122009 | 0.85 | CCR2 (0.41) | ADRA1DCCR2ADRA1AADRA1BL3MBTL1 | |
| SCHEMBL12997839 | 0.84 | DDR1 (0.54) | DDR1 | |
| SCHEMBL28323467 | 0.83 | CCR2 (0.46) | ADRA1DCCR2ADRA1AADRA1BTRPV4 | |
| Hydrochloric Acid SCHEMBL1262779 | 0.82 | DDR1 (0.52) | DDR1 | |
| SCHEMBL1039443 | 0.81 | ADRA1D (0.48) | ADRA1DCCR2ADRA1AADRA1BTRPV4 | |
| SCHEMBL1016174 | 0.81 | CCR2 (0.45) | ADRA1DCCR2ADRA1AADRA1BTRPV4 | |
| SCHEMBL1804210 | 0.81 | CYP2A6 (0.39) | ADRA1DCCR2TRPV4CYP2A6DDR1 | |
| Hydrochloric Acid SCHEMBL1016268 | 0.81 | CA1 (0.41) | TRPV4CYP2A6MEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010137620-A1 | PHENOXYETHYLAMINE DERIVATIVE | 武田薬品工業株式会社 (JP) | 2010-12-02 | — | — | WO | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | ADRA1D 1125/4885CCR2 1277/4885ADRA1A 1149/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | ADRA1D 1125/4885CCR2 1277/4885ADRA1A 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.